You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1/PD-L1 inhibitor therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on

Recruiting
  • Hepatocellular Carcinoma
  • Acute Rejection
    • Beijing, Beijing, China
      Beijing Tsinghua Changgung Hospital
    Jun 6, 2022

    Metastatic Urothelial Cancer Trial in China (Enfortumab vedotin)

    Active, not recruiting
    • Metastatic Urothelial Cancer
    • Enfortumab vedotin
    • Beijing, China
    • +7 more
    Aug 23, 2022

    Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

    Not yet recruiting
    • Metastatic Pancreatic Cancer
    • Durvalumab
    • Rintatolimod
    • Rotterdam, Zuid-Holland, Netherlands
      Erasmus MC
    Jun 23, 2023

    Metastasis, Solid Tumor Trial (Peptide Alarm Therapy (PAT))

    Not yet recruiting
    • Metastasis
    • Solid Tumor
    • Peptide Alarm Therapy (PAT)
    • (no location specified)
    Nov 2, 2022

    NSCLC Trial in Zhengzhou (L-TIL, Tislelizumab, Docetaxel)

    Recruiting
    • Non-small Cell Lung Cancer
    • L-TIL, Tislelizumab, Docetaxel
    • Zhengzhou, Henan, China
      No.127 Dongming Road
    May 17, 2023

    Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 Trial (Nivolumab,

    Withdrawn
    • Lung Non-Small Cell Carcinoma
    • +12 more
    • (no location specified)
    May 24, 2022

    Extensive-Stage Small Cell Lung Cancer Trial in Beijing (Surufatinib, Anti-PD-1/L1)

    Not yet recruiting
    • Extensive-Stage Small Cell Lung Cancer
    • Beijing, China
      Chinese PLA General Hospital
    Aug 18, 2022

    Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • HAIC
    • +8 more
    • Quanzhou, Fujian, China
    • +1 more
    Jan 26, 2023

    Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • TACE
    • +8 more
    • Quanzhou, Fujian, China
    • +3 more
    Jan 29, 2023

    Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors Trial in Baltimore (Nivolumab, Relatlimab)

    Recruiting
    • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
    • MSI-H Tumors
    • Baltimore, Maryland
      Sidney Kimmel Comprehensive Cancer Center
    Mar 14, 2022

    Metastatic Cancer, Urothelial Carcinoma Trial (avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin)

    Not yet recruiting
    • Metastatic Cancer
    • Urothelial Carcinoma
    • avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
    • (no location specified)
    Dec 19, 2022

    Advanced Solid Cancers, Advanced Solid Cancers Refractory to PD-1 Trial in United States (AGEN1884)

    Completed
    • Advanced Solid Cancers
    • Advanced Solid Cancers Refractory to PD-1
    • Duarte, California
    • +10 more
    Apr 28, 2022

    Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

    Recruiting
    • Non Small Cell Lung Cancer
    • anti-PD-1 or anti-PD-L1
    • +2 more
    • Shanghai, China
      Oncology Department, Shanghai Chest Hospital
    Jul 26, 2022

    Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation

    Completed
    • Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
    • Anti-PD-1 or anti-PD-L1
    • Montpellier, France
      UH Montpellier
    Dec 22, 2021

    Advanced Lung Cancer Trial (6MW3211)

    Not yet recruiting
    • Advanced Lung Cancer
    • (no location specified)
    Jun 20, 2022

    Hepatocellular Carcinoma Trial in Beijing, Shanghai, Shenyang (SCG101, PD1/PD-L1 checkpoint inhibitor)

    Recruiting
    • Hepatocellular Carcinoma
    • SCG101
    • PD1/PD-L1 checkpoint inhibitor
    • Beijing, China
    • +3 more
    May 7, 2022

    Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

    Completed
    • Advanced Solid Tumor
    • Inosine 0.2g orally 3 times/day
    • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
    • Beijing, Beijing, China
      Qin li
    Mar 30, 2023

    Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

    Recruiting
    • Colorectal Cancer
    • +3 more
    • Neoadjuvant therapy with PD-L1 inhibitor
    • Guangzhou, Guangdong, China
      the Third Affiliated Hospital of Sun Yat-Sen University
    May 10, 2022

    Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

    Recruiting
    • Advanced Solid Tumor
    • Refractory Tumor
    • Suzhou, China
      The Second Affiliated Hospital of SchoowUniversity
    Mar 29, 2023

    Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

    Not yet recruiting
    • Advanced Non Small Cell Lung Cancer
    • (no location specified)
    Oct 24, 2023

    Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Lung Cancer
    • Centipeda minima+PD-1/PD-L1 inhibitor
    • PD-1/PD-L1 inhibitor
    • (no location specified)
    Feb 17, 2023

    Rare Tumor, Refractory Tumor Trial in Shanghai (Gefitinib, Erlotinib, Afatinib)

    Recruiting
    • Rare Tumor
    • Refractory Tumor
    • Shanghai, Shanghai, China
      Shanghai Changzheng Hospital
    Feb 16, 2022

    Advanced Malignant Skin Tumor, Metastatic Malignant Skin Tumor Trial in Los Angeles (drug, biological, other)

    Recruiting
    • Advanced Malignant Skin Neoplasm
    • Metastatic Malignant Skin Neoplasm
    • Los Angeles, California
    • +1 more
    Apr 1, 2021

    Unresectable/Metastatic Melanoma Trial in Australia, Canada (Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor

    Recruiting
    • Unresectable/Metastatic Melanoma
    • Intermittent PD-1 inhibitor therapy
    • Continuous PD-1 inhibitor therapy
    • Coffs Harbour, New South Wales, Australia
    • +29 more
    Jan 5, 2022

    Efficacy, Safety Trial (PD-L1 inhibitor)

    Not yet recruiting
    • Efficacy
    • Safety
    • PD-L1 inhibitor
    • (no location specified)
    Apr 6, 2022